The PET Imaging Center’s Beginnings
The Biomedical Research Foundation of Northwest Louisiana opened the PET Imaging Center in 1995. This center was one of the first centers offering imaging and radiopharmaceutical manufacturing capabilities in the southern United States. Since those early beginnings where we may have scanned one patient per month, the Center has grown into a busy facility, which has provided more than 50,000 scans. While our expertise in PET Imaging is very broad, most of our work uses 18F-FDG for oncology, 18F-NaF for bone imaging, Ammonia for cardiac imaging and various neurologic tracers for brain imaging. PET Imaging is a powerful tool for clinical trials and allows us to participate in many different trials utilizing PET Imaging.
Tracing Diseases to Improve Patient Diagnoses and Treatment
The Center also works with a variety of radiopharmaceuticals used for direct therapeutic purposes. We administer radiopharmaceuticals for a variety of diseases, but prostate cancer is the most common. This is an exciting, emerging field, which we are growing due to our focus on research. Because of our capability and interest, we have multiple clinical trials available to evaluate the use of experimental radionuclidic therapies.
Physician and Patient Information
The CMIT PET Imaging Center receives referrals from many physicians in the region. We go above and beyond to provide patient care and to provide excellent results and interpretations to the treating physicians.
The CMIT Pet Imaging Center provides clinical care to thousands of patients every year. PET imaging procedures and radionuclidic therapy treatments are performed daily as well as multiple opportunities for patients to participate in cutting-edge clinical trials. Patients who choose CMIT receive excellent care during their procedures, including consultation with on-site nuclear medicine physicians. Our physicians provide high-quality interpretations, which will provide the best information available to make treatment plans.
CMIT offers an array of PET scans with different radiopharmaceuticals for many different indications. We mainly target cancer, as FDG-PET is the gold standard for diagnosis, staging, and therapy evaluation for many cancers. We also routinely image the heart and brain, scoping out cell behavior that may indicate issues like artery disease, Alzheimer’s disease and Parkinson’s disease. Radionuclidic therapies are also available.